Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors

25 Mar 2014

Abstract excerpt

Adoptive transfer of tumor-infiltrating lymphocytes (TILs) can mediate regression of metastatic melanoma; however, TILs are a heterogeneous population, and there are no effective markers to specifically identify and select the repertoire of tumor-reactive and mutation-specific CD8⁺ lymphocytes. The lack of biomarkers limits the ability to study these cells and develop strategies to enhance clinical efficacy and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24667641
DOI: 10.1172/jci73639

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumorsPMID 24667641Read ↗

Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanomaSemantic proximity Read ↗

Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancersSemantic proximity Read ↗

Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor.Semantic proximity Read ↗

Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patientsSemantic proximity Read ↗

Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1.Semantic proximity Read ↗

Tumor reactivity assessment using clonal expression (TRACE) reveals tumor reactive CD8 <sup>+</sup> T cell heterogeneity across solid tumorsSemantic proximity Read ↗

Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cellsSemantic proximity Read ↗

The mutational load and a T-cell inflamed tumor phenotype identify ovarian cancer patients rendering tumor-reactive T cells from PD-1+ tumor-infiltrating lymphocytesSemantic proximity Read ↗

Circulating tumor-reactive KIR+CD8+ T cells suppress anti-tumor immunity in patients with melanomaSemantic proximity Read ↗

Phenotypic and Functional Characteristics of CD8+ T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma.Semantic proximity Read ↗

PD-1 expression conditions T cell avidity within an antigen-specific repertoireSemantic proximity Read ↗

Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.